2003 ER Patients Provider 
FDA Law Blog
SEPTEMBER 6, 2021
Typically, generic sponsors carve out a patent-protected indication or patient population, but technically, any method of use can be carved out as long as FDA determines that the product can still be used safely and effectively without the patent-protected information. The catch is, as we have learned from the GSK v.
GeriPal
APRIL 20, 2023
Today we talk with Margot Kushel about how we got here, including: That sense of powerlessness as a clinician when you “fix up” a patient in the hospital, only to discharge them to the street knowing things will fall apart. It was in the mid-nineties, and about half of the patients that we cared for in the inpatient service were homeless.
Expert insights. Personalized for you.
52 
Let's personalize your content